AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

9,995.00p
   
  • Change Today:
      26.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.30m
  • Volume: 1,072,871
  • Market Cap: £154,953m
  • RiskGrade: 123
  • Beta: 0.87

Latest ShareCast News

AstraZeneca's Tagrisso recommended for EU approval

By Iain Gilbert

Date: Monday 18 Nov 2024

(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Tagrisso asset had received a recommendation for EU approval on the back of LAURA Phase III trial results, which revealed it had extended median progression-free survival to more than three years.

Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems

By Alexander Bueso

Date: Sunday 17 Nov 2024

(Sharecast News) - America's President has authorised Ukraine to employ long-range ATACMS supplied by the US to strike targets inside Russia. More specifically, Kyiv will now be allowed to strike targets within the Kursk region, the New York Times reported. Speculation may increase that permission from Britain, the US and France to do the same with Storm Shadow missiles could follow. Joe Biden's decision is said to have been triggered by the appearance of North Korean troops in the Kursk region. - The Sunday Telegraph

London close: Stocks end turbulent week in the red

By Josh White

Date: Friday 15 Nov 2024

(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.

Director dealings: AstraZeneca CEO ups stake 15-Nov-2024 ShareCast
London close: Stocks sink as UK jobless rate rises 12-Nov-2024 ShareCast
AstraZeneca upgrades full-year guidance amid str... 12-Nov-2024 ShareCast
AstraZeneca "excited" by positive results in Tez... 08-Nov-2024 ShareCast
AstraZeneca says does not comment on media repor... 05-Nov-2024 ShareCast
AstraZeneca China president under investigation 30-Oct-2024 ShareCast
AstraZeneca's nerve damage treatment recommended... 21-Oct-2024 ShareCast
Hutchmed reports positive results from AstraZene... 16-Oct-2024 ShareCast
AstraZeneca enters into exclusive license agreem... 07-Oct-2024 ShareCast
AstraZeneca's Tagrisso gets new US lung cancer a... 26-Sep-2024 ShareCast
London close: Stocks finish higher after slew of... 23-Sep-2024 ShareCast
AstraZeneca breast cancer drug trial fails to im... 23-Sep-2024 ShareCast
AstraZeneca's inflammatory disease drug Fasenra ... 18-Sep-2024 ShareCast
London close: Stocks finish firmer in subdued tr... 13-Sep-2024 ShareCast
London close: Stocks mixed on latest UK jobs data 10-Sep-2024 ShareCast
AstraZeneca shares drop on lung cancer trial upd... 10-Sep-2024 ShareCast
London close: Stocks slip on relatively quiet Fr... 16-Aug-2024 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 9,995.00p
Change Today 26.00p
% Change 0.26 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 1,072,871
Shares Issued 1,550.30m
Market Cap £154,953m
Beta 0.87
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average
88% below the sector average88% below the sector average88% below the sector average88% below the sector average88% below the sector average
Price Trend
27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Income
78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 21-Nov-2024

Time Volume / Share Price
12:53 26 @ 9,995.00p
12:53 28 @ 9,995.00p
12:53 29 @ 9,996.00p
12:53 0 @ 9,996.00p
12:52 216 @ 9,998.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page